摘要:
A process for producing solid combination tablets which have at least two phases comprises molding a melt of a polymeric binder with or without at least one active ingredient, there being at least one solid product, which may contain an active ingredient incorporated into the still plastic composition during the molding step.
摘要:
A process for preparing salts of pharmaceutical active substances which have acidic groups by reacting the carboxylic acids with a base in the melt, wherein the acids are reacted with at least the stoichiometric amount of a base in an extruder.
摘要:
The present invention relates to a process for the production of lenticular tablets by melt calendering in which molding rolls with depressions in the shape of segments of an ellipsoid are used. The process according to the invention affords tablets which are easily deflashed and in which the tablet residue to be abraded when there is a displacement between the upper and lower half of the tablet is small.
摘要:
The present invention is a process for the production of covered tablets by melt calendering in which the melt containing active ingredient is introduced between two sheets of the covering material into the molding rolls.
摘要:
A process for the production of divisible tablets by melt calendering in which two molding rolls are combined together, at least one of which has depressions with at least one bar which extends up to the surface line of the molding roll and forms a score.
摘要:
Solid preparations are obtainable by melt extrusion ofA) at least one active compound,B) a mixture ofB1) from 10 to 90% by weight of a water-soluble, thermoplastic polymer, andB2) from 10 to 90% by weight of a low-substituted hydroxypropylcellulose, andC) from 0 to 50% by weight, based on the total amount of the preparation, of customary pharmaceutical auxiliaries.
摘要:
The present invention provides a pharmaceutical dosage formulation, and more particularly, a pharmaceutical dosage formulation comprising an HIV protease inhibitor.
摘要:
Solid drug forms are produced by mixing and melting at least one pharmacologically acceptable polymeric binder and at least one pharmaceutical active ingredient, with or without conventional pharmaceutical additives, in the absence of a solvent to give a plastic mixture and shaping the mixture to the required drug form by extrusion, where the shaping takes place in two steps, with the extrudate being broken into shaped articles in a first step, and these shaped articles being rounded off in a second step in the plastic state.
摘要:
A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described.
摘要:
A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.